Insider Trading activities of Xenoport Inc insiders. , Part 2

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Xenoport Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Xenoport Inc since year 2005. (See page 1 of this report.) Table 2 shows the detailed insider transactions of Xenoport Inc since 2005. The reporting company's ticker symbol is XNPT. The reporting company's CIK number is 1130591.
The total value of stock buying since 2005 is $21,182,574.
The total value of stock sales since 2005 is $24,055,543.
The total value of stock option exercises since 2005 is $2,510,257.


Go to page:  1   2 

Table 2. Detailed insider stock purchases, sales, and option exercises of Xenoport Inc insiders (XNPT) , Part 2
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2011-03-14 Savello David R (SVP, Development) Option Ex 10,000 .00 0
2011-03-14 Harris William G (SVP, Finance and CFO) Option Ex 10,000 .00 0
2011-03-14 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 10,000 .00 0
2011-01-31 Bosko Gianna M (SVP, CAO, GC and secretary) Option Ex 250 .00 0
2011-01-31 Savello David R (SVP, Development) Option Ex 500 .00 0
2011-01-31 Barrett Ronald W (Chief Executive Officer) Option Ex 1,250 .00 0
2011-01-31 Harris William G (SVP, Finance and CFO) Option Ex 500 .00 0
2011-01-31 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 625 .00 0
2011-01-28 Bosko Gianna M (SVP, CAO, GC and secretary) Option Ex 563 .00 0
2011-01-28 Angotti Vincent (SVP & CCO) Option Ex 1,000 .00 0
2011-01-28 Savello David R (SVP, Development) Option Ex 875 .00 0
2011-01-28 Harris William G (SVP, Finance and CFO) Option Ex 1,000 .00 0
2011-01-28 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,250 .00 0
2011-01-13 Bosko Gianna M (SVP, CAO, GC and secretary) Option Ex 750 .00 0
2011-01-13 Angotti Vincent (SVP & CCO) Option Ex 1,250 .00 0
2011-01-13 Savello David R (SVP, Development) Option Ex 1,250 .00 0
2011-01-13 Barrett Ronald W (Chief Executive Officer) Option Ex 10,000 .00 0
2011-01-13 Harris William G (SVP, Finance and CFO) Option Ex 1,250 .00 0
2011-01-13 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,250 .00 0
2010-11-12 Fenton Dennis M (Director) Buy 1,300 7.90 10,273
2010-08-10 Angotti Vincent (SVP & CCO) Option Ex 2,500 .00 0
2010-08-02 Stamler David A (SVP, Chief Medical Officer) Option Ex 2,500 .00 0
2010-02-24 Savello David R (SVP, Development) Option Ex 8,335 .00 0
2010-02-24 Barrett Ronald W (Chief Executive Officer) Option Ex 12,500 .00 0
2010-02-24 Harris William G (SVP, Finance and CFO) Option Ex 1,667 .00 0
2010-02-24 Gallop Mark A (SVP, Research) Option Ex 1,667 .00 0
2010-02-24 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 2,085 .00 0
2010-02-24 Rieflin William Jl (President) Option Ex 2,917 .00 0
2010-02-01 Savello David R (SVP, Development) Option Ex 500 .00 0
2010-02-01 Barrett Ronald W (Chief Executive Officer) Option Ex 1,250 .00 0
2010-02-01 Harris William G (SVP, Finance and CFO) Option Ex 500 .00 0
2010-02-01 Gallop Mark A (SVP, Research) Option Ex 500 .00 0
2010-02-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 2,000 18.55 37,094
2010-02-01 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 2,625 .75 3,000
2010-02-01 Rieflin William Jl (President) Option Ex 1,250 .00 0
2010-01-28 Stamler David A (SVP, Chief Medical Officer) Option Ex 1,000 .00 0
2010-01-28 Angotti Vincent (SVP & CCO) Option Ex 1,000 .00 0
2010-01-28 Savello David R (SVP, Development) Option Ex 875 .00 0
2010-01-28 Harris William G (SVP, Finance and CFO) Option Ex 1,000 .00 0
2010-01-28 Gallop Mark A (SVP, Research) Option Ex 750 .00 0
2010-01-28 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,250 .00 0
2010-01-04 Cundy Kenneth C (SVP, Preclinical Development) Sale 2,000 19.16 38,324
2010-01-04 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 2,000 1.50 3,000
2009-10-06 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 22.00 22,000
2009-10-06 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,000 1.80 1,800
2009-09-17 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 24.65 24,649
2009-09-17 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,000 1.80 1,800
2009-08-26 Barrett Ronald W (Chief Executive Officer) Option Ex 48,147 2.25 108,330
2009-08-10 Stamler David A (SVP, Chief Medical Officer) Option Ex 2,500 .00 0
2009-08-10 Angotti Vincent (SVP & CCO) Option Ex 2,500 .00 0
2009-07-10 Freund John Gordon (Director) Buy 5,000 19.02 95,079
2009-07-08 Freund John Gordon (Director) Buy 130,000 19.00 2,470,000
2009-07-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 23.29 23,291
2009-07-01 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,000 1.80 1,800
2009-06-11 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 22.00 22,000
2009-06-11 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,000 1.80 1,800
2009-03-25 Cundy Kenneth C (SVP, Preclinical Development) Sale 544 22.00 11,968
2009-03-25 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 544 1.80 979
2009-02-17 Savello David R (SVP, Development) Option Ex 4,167 .00 0
2009-02-17 Barrett Ronald W (Chief Executive Officer) Option Ex 6,250 .00 0
2009-02-17 Harris William G (SVP, Finance and CFO) Option Ex 834 .00 0
2009-02-17 Gallop Mark A (SVP, Research) Option Ex 834 .00 0
2009-02-17 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,042 .00 0
2009-02-17 Rieflin William Jl (President) Option Ex 1,459 .00 0
2009-02-02 Cundy Kenneth C (SVP, Preclinical Development) Sale 3,000 26.87 80,396
2009-02-02 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 3,000 1.80 5,400
2009-01-30 Savello David R (SVP, Development) Option Ex 500 .00 0
2009-01-30 Barrett Ronald W (Chief Executive Officer) Option Ex 1,250 .00 0
2009-01-30 Harris William G (SVP, Finance and CFO) Option Ex 500 .00 0
2009-01-30 Gallop Mark A (SVP, Research) Option Ex 500 .00 0
2009-01-30 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 625 .00 0
2009-01-30 Rieflin William Jl (President) Option Ex 1,250 .00 0
2009-01-14 Stamler David A (SVP, Chief Medical Officer) Option Ex 3,309 .00 0
2009-01-14 Angotti Vincent (SVP & CCO) Option Ex 1,847 .00 0
2009-01-14 Savello David R (SVP, Development) Option Ex 3,025 .00 0
2009-01-14 Barrett Ronald W (Chief Executive Officer) Option Ex 9,872 .00 0
2009-01-14 Harris William G (SVP, Finance and CFO) Option Ex 3,065 .00 0
2009-01-14 Gallop Mark A (SVP, Research) Option Ex 2,578 .00 0
2009-01-14 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 3,104 .00 0
2009-01-14 Rieflin William Jl (President) Option Ex 5,592 .00 0
2009-01-02 Cundy Kenneth C (SVP, Preclinical Development) Sale 3,000 26.94 79,776
2009-01-02 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 3,000 1.65 4,950
2008-12-01 Gallop Mark A (SVP, Research) Sale 1,200 29.88 35,858
2008-11-10 Rieflin William Jl (President) Option Ex 18,887 15.00 283,305
2008-11-03 Gallop Mark A (SVP, Research) Sale 3,000 42.01 126,177
2008-11-03 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 42.02 42,015
2008-11-03 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,000 1.50 1,500
2008-10-01 Gallop Mark A (SVP, Research) Sale 3,000 48.76 145,999
2008-10-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 3,000 48.63 145,887
2008-10-01 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 3,000 1.50 4,500
2008-09-12 Gallop Mark A (SVP, Research) Sale 1,000 50.00 50,000
2008-09-02 Harris William G (SVP, Finance and CFO) Sale 1,500 49.04 73,566
2008-09-02 Gallop Mark A (SVP, Research) Sale 3,000 49.16 147,489
2008-09-02 Cundy Kenneth C (SVP, Preclinical Development) Sale 3,000 49.07 147,219
2008-09-02 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 3,000 1.50 4,500
2008-08-19 Wierenga Wendall (Director) Sale 4,000 48.55 194,196
2008-08-14 Gallop Mark A (SVP, Research) Sale 1,000 50.00 50,000
2008-08-14 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 49.00 49,000
2008-08-14 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,000 1.50 1,500
2008-08-01 Harris William G (SVP, Finance and CFO) Sale 1,500 45.86 68,784
2008-08-01 Gallop Mark A (SVP, Research) Sale 5,500 45.90 251,975
2008-08-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 2,000 45.88 91,750
2008-08-01 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 2,000 1.50 3,000
2008-07-23 Harris William G (SVP, Finance and CFO) Sale 500 45.00 22,500
2008-07-23 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 44.52 44,517
2008-07-23 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,000 1.50 1,500
2008-07-14 Gallop Mark A (SVP, Research) Sale 1,000 40.18 40,183
2008-07-01 Harris William G (SVP, Finance and CFO) Sale 1,000 38.07 38,074
2008-07-01 Gallop Mark A (SVP, Research) Sale 2,000 38.11 76,222
2008-07-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 38.10 38,096
2008-07-01 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,000 1.50 1,500
2008-06-16 Berns Paul L (Director) Sale 12,500 42.05 525,600
2008-06-16 Berns Paul L (Director) Option Ex 12,500 12.86 160,750
2008-06-02 Harris William G (SVP, Finance and CFO) Sale 1,000 41.88 41,876
2008-06-02 Gallop Mark A (SVP, Research) Sale 3,000 41.91 125,593
2008-06-02 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 41.88 41,882
2008-06-02 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 651 1.50 976
2008-05-14 Harris William G (SVP, Finance and CFO) Sale 500 45.06 22,530
2008-05-14 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 44.04 44,040
2008-05-13 Freund John Gordon (Director) Buy 97,000 43.59 4,228,036
2008-05-12 Savello David R (SVP, Development) Sale 11,192 42.86 479,700
2008-05-12 Freund John Gordon (Director) Buy 147,008 43.23 6,354,714
2008-05-09 Freund John Gordon (Director) Buy 109,325 40.35 4,411,263
2008-05-01 Harris William G (SVP, Finance and CFO) Sale 1,000 42.60 42,598
2008-05-01 Gallop Mark A (SVP, Research) Sale 3,000 42.53 127,697
2008-05-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 42.61 42,614
2008-04-04 Cundy Kenneth C (SVP, Preclinical Development) Sale 3,000 44.17 132,510
2008-04-01 Harris William G (SVP, Finance and CFO) Sale 1,000 42.05 42,046
2008-04-01 Gallop Mark A (SVP, Research) Sale 3,000 41.99 125,975
2008-04-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 42.09 42,087
2008-03-14 Friedman Cathy (Director) Buy 4,600 42.71 196,456
2008-03-14 Freund John Gordon (Director) Buy 15,156 41.60 630,504
2008-02-19 Savello David R (SVP, Development) Option Ex 4,168 .00 0
2008-02-19 Barrett Ronald W (Chief Executive Officer) Sale 8,000 54.57 435,407
2008-02-19 Barrett Ronald W (Chief Executive Officer) Option Ex 6,250 .00 0
2008-02-19 Harris William G (SVP, Finance and CFO) Option Ex 834 .00 0
2008-02-19 Gallop Mark A (SVP, Research) Option Ex 834 .00 0
2008-02-19 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 1,043 .00 0
2008-02-19 Rieflin William Jl (President) Option Ex 1,459 .00 0
2008-02-12 Savello David R (SVP, Development) Option Ex 6,830 13.42 91,658
2008-02-01 Harris William G (SVP, Finance and CFO) Sale 1,500 61.75 92,628
2008-02-01 Gallop Mark A (SVP, Research) Sale 4,000 61.75 246,984
2008-02-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 4,000 61.79 247,251
2008-01-16 Barrett Ronald W (Chief Executive Officer) Sale 8,000 60.88 486,848
2008-01-02 Harris William G (SVP, Finance and CFO) Sale 1,500 56.00 83,997
2008-01-02 Gallop Mark A (SVP, Research) Sale 4,000 55.97 223,907
2008-01-02 Cundy Kenneth C (SVP, Preclinical Development) Sale 4,000 56.01 224,076
2007-12-17 Barrett Ronald W (Chief Executive Officer) Sale 8,000 54.55 435,909
2007-12-05 Wierenga Wendall (Director) Sale 3,000 54.85 164,544
2007-12-03 Harris William G (SVP, Finance and CFO) Sale 1,500 53.32 79,975
2007-12-03 Cundy Kenneth C (SVP, Preclinical Development) Sale 4,000 53.41 212,870
2007-11-15 Barrett Ronald W (Chief Executive Officer) Sale 8,000 54.28 434,036
2007-11-01 Harris William G (SVP, Finance and CFO) Sale 1,500 49.45 74,179
2007-11-01 Gallop Mark A (SVP, Research) Sale 3,000 49.52 148,194
2007-11-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 4,000 49.26 197,343
2007-10-15 Barrett Ronald W (Chief Executive Officer) Sale 8,400 49.89 419,373
2007-10-01 Harris William G (SVP, Finance and CFO) Sale 1,500 49.30 73,942
2007-10-01 Gallop Mark A (SVP, Research) Sale 3,000 49.30 147,915
2007-10-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 4,000 49.28 197,049
2007-09-18 Cundy Kenneth C (SVP, Preclinical Development) Sale 2,000 45.00 90,000
2007-09-17 Barrett Ronald W (Chief Executive Officer) Sale 8,400 44.28 371,993
2007-09-04 Gallop Mark A (SVP, Research) Sale 3,000 41.82 125,451
2007-09-04 Cundy Kenneth C (SVP, Preclinical Development) Sale 2,000 41.84 83,678
2007-08-15 Barrett Ronald W (Chief Executive Officer) Sale 8,400 39.38 330,810
2007-08-01 Gallop Mark A (SVP, Research) Sale 3,000 43.04 129,126
2007-08-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 2,000 43.02 86,042
2007-07-16 Barrett Ronald W (Chief Executive Officer) Sale 8,400 46.07 387,022
2007-07-03 Cundy Kenneth C (SVP, Preclinical Development) Sale 2,000 45.00 90,000
2007-07-02 Gallop Mark A (SVP, Research) Sale 3,000 44.82 134,463
2007-07-02 Cundy Kenneth C (SVP, Preclinical Development) Sale 2,000 44.84 89,690
2007-06-15 Barrett Ronald W (Chief Executive Officer) Sale 8,400 46.12 387,459
2007-06-04 Savello David R (SVP, Development) Sale 13,431 44.44 596,806
2007-06-04 Savello David R (SVP, Development) Option Ex 13,431 13.42 180,244
2007-06-04 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,500 45.00 67,500
2007-06-01 Gallop Mark A (SVP, Research) Sale 3,000 45.06 135,165
2007-06-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 2,500 45.02 112,540
2007-05-30 Cundy Kenneth C (SVP, Preclinical Development) Sale 2,000 45.00 90,000
2007-05-22 Cundy Kenneth C (SVP, Preclinical Development) Sale 5,000 42.91 214,549
2007-05-22 Cundy Kenneth C (SVP, Preclinical Development) Option Ex 5,000 1.50 7,500
2007-05-16 Wierenga Wendall (Director) Sale 5,000 41.15 205,750
2007-05-15 Barrett Ronald W (Chief Executive Officer) Sale 8,400 41.80 351,146
2007-05-15 Nussbacher Kenneth J (Director) Sale 5,403 42.08 227,347
2007-05-14 Gallop Mark A (SVP, Research) Sale 8,000 40.84 326,728
2007-05-14 Nussbacher Kenneth J (Director) Sale 4,597 41.16 189,230
2007-05-10 Roberts Bryan E (Director) Sale 70 41.11 2,877
2007-05-01 Gallop Mark A (SVP, Research) Sale 3,000 41.68 125,040
2007-05-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 2,000 41.66 83,330
2007-04-26 Cundy Kenneth C (SVP, Preclinical Development) Sale 100 44.24 4,424
2007-04-25 Barrett Ronald W (Chief Executive Officer) Sale 2,700 38.12 102,934
2007-04-25 Gallop Mark A (SVP, Research) Sale 1,000 38.26 38,264
2007-04-25 Cundy Kenneth C (SVP, Preclinical Development) Sale 900 38.00 34,200
2007-04-16 Barrett Ronald W (Chief Executive Officer) Sale 5,700 29.75 169,553
2007-03-22 Savello David R (SVP, Development) Option Ex 11,192 13.42 150,196
2007-03-22 Barrett Ronald W (Chief Executive Officer) Sale 3,400 25.00 85,000
2007-03-15 Barrett Ronald W (Chief Executive Officer) Sale 3,000 24.65 73,947
2007-03-14 Harris William G (SVP, Finance and CFO) Sale 15,000 24.72 370,739
2007-03-09 Gallop Mark A (SVP, Research) Sale 2,000 25.79 51,584
2007-03-01 Gallop Mark A (SVP, Research) Sale 3,000 25.20 75,603
2007-03-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 25.20 25,201
2007-02-15 Barrett Ronald W (Chief Executive Officer) Sale 5,700 28.24 160,909
2007-02-08 Barrett Ronald W (Chief Executive Officer) Sale 2,700 30.00 81,000
2007-02-08 Gallop Mark A (SVP, Research) Sale 1,000 30.00 30,000
2007-02-01 Gallop Mark A (SVP, Research) Sale 3,000 24.01 72,042
2007-02-01 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 24.07 24,068
2007-01-16 Barrett Ronald W (Chief Executive Officer) Sale 5,700 24.66 140,876
2007-01-03 Gallop Mark A (SVP, Research) Sale 3,000 24.31 72,930
2007-01-03 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 24.30 24,296
2006-12-22 Cundy Kenneth C (SVP, Preclinical Development) Sale 1,000 25.01 25,008
2006-12-15 Barrett Ronald W (Chief Executive Officer) Sale 5,700 25.18 143,544
2006-12-15 Wierenga Wendall (Director) Sale 4,000 25.02 100,080
2006-12-01 Gallop Mark A (SVP, Research) Sale 3,000 26.09 78,141
2006-11-15 Gallop Mark A (SVP, Research) Buy 306 19.98 6,112
2006-11-06 Wierenga Wendall (Director) Sale 5,000 23.91 119,540
2006-11-01 Barrett Ronald W (Chief Executive Officer) Sale 3,000 23.78 71,346
2006-11-01 Gallop Mark A (SVP, Research) Sale 3,000 23.77 71,255
2006-10-16 Barrett Ronald W (Chief Executive Officer) Sale 3,000 23.88 71,655
2006-10-02 Gallop Mark A (SVP, Research) Sale 3,000 20.56 61,932
2006-09-01 Gallop Mark A (SVP, Research) Sale 3,000 21.75 65,198
2006-08-29 Gallop Mark A (SVP, Research) Sale 1,000 20.02 20,015
2006-08-01 Gallop Mark A (SVP, Research) Sale 2,000 16.85 33,702
2006-07-06 Gallop Mark A (SVP, Research) Sale 1,000 20.00 20,000
2006-07-03 Gallop Mark A (SVP, Research) Sale 2,000 18.93 37,858
2006-06-01 Gallop Mark A (SVP, Research) Sale 3,000 22.31 66,942
2006-05-01 Gallop Mark A (SVP, Research) Sale 3,000 22.52 67,560
2006-04-03 Gallop Mark A (SVP, Research) Sale 3,000 21.61 64,824
2006-03-15 Gallop Mark A (SVP, Research) Sale 1,000 20.02 20,020
2006-03-01 Gallop Mark A (SVP, Research) Sale 2,000 19.08 38,152
2006-02-24 Harris William G (SVP, Finance and CFO) Sale 22,000 18.62 407,576
2006-02-15 Tollefson Gary D (Director) Option Ex 1,735 3.60 6,246
2006-01-03 Gallop Mark A (SVP, Research) Sale 2,000 17.84 35,684
2005-11-28 Cundy Kenneth C (SVP, Preclinical Development) Buy 700 13.00 9,100
2005-11-16 Barrett Ronald W (Chief Executive Officer) Buy 2,380 8.92 21,241
2005-11-16 Dower William J (VP, Discovery Biology) Buy 1,540 8.92 13,744
2005-11-16 Gallop Mark A (SVP, Research) Buy 1,733 8.92 15,467
2005-11-16 Cundy Kenneth C (SVP, Preclinical Development) Buy 1,694 8.92 15,118
2005-11-16 Rieflin William Jl (President) Buy 2,272 8.92 20,277
2005-09-13 Freund John Gordon (Director) Buy 4,200 15.11 63,478
2005-09-07 Freund John Gordon (Director) Buy 7,480 13.11 98,062
2005-09-06 Freund John Gordon (Director) Buy 1,520 13.00 19,760
Go to page:  1   2 

Insider trading activities including stock purchases, stock sales, and option exercises of XNPT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Xenoport Inc (symbol XNPT, CIK number 1130591) see the Securities and Exchange Commission (SEC) website.